Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03747432
Other study ID # UMCLJTAVR
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 15, 2019
Est. completion date June 30, 2021

Study information

Verified date May 2023
Source University Medical Centre Ljubljana
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aortic valve stenosis is the most common valvular heart disease in the developed world, affecting 3,9% of population over 70 years of age. If untreated it carries a poor prognosis, leading to heart failure and death in 2 years after first symptom presentation. Treatment of choice for severe aortic stenosis is surgical aortic valve replacement. A new treatment option for severe aortic stenosis emerged in the last decade - Transcatheter Aortic Valve Replacement (TAVR). This minimally invasive method was formerly reserved for high risk patients deemed unfit for surgical aortic valve replacement. Increasing use throughout the developed world and recent studies have established TAVR as a safe and viable treatment option also for intermediate-risk patients. TAVR not only enables a less aggressive surgical approach, but also a less invasive type of anaesthesia. Anaesthesiologists are trying to modify the type of anaesthesia in the way of minimally invasive approach, aiming to improve the overall outcome. TAVR can be performed under general anaesthesia or procedural sedation (PS). From the start, TAVR was performed solely under general anaesthesia. Over time the procedure became routine and the anaesthesiologists started to commonly decide for PS. Many US and European retrospective studies have established PS to be a safe and compelling method of anaesthetic care for TAVR procedures with a favorable perioperative course, less complications, shorter intensive care unit and in-hospital stay and lower early mortality, when performed by an experienced anaesthesia team. There are many anaesthesia agents currently accepted for PS in everyday anaesthesia practice. Presently, reliable data from studies comparing different agents for PS for TAVR procedures is scarce. Most of it comes from retrospective nonrandomized trials. Propofol is a popular anaesthetic agent for PS. According to current studies, it is a safe anaesthetic agent with favorable pharmacokinetic and pharmacodynamic profiles with quite low incidence of side effects. In recent years, dexmedetomidine has been commonly used for PS having analgesic properties inclusive of its anaesthetic properties. In addition, dexmedetomidine is associated with a lesser degree of respiratory depression as to other anaesthetic agents. Patient comfort is also believed to be improved with dexmedetomidine. Studies comparing outcomes of PS with propofol versus dexmedetomidine for different non-cardiac and interventional procedures showed benefits of dexmedetomidine, owing to its analgesic properties and preferable respiratory parameters. The aim of this study is to compare the outcome of patients undergoing TAVR under PS with dexmedetomidine against those undergoing TAVR under PS with propofol. With the results the investigators aim to aid in defining the optimal anaesthetic agent for PS for TAVR and possibly other interventional cardiology procedures.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admission to University Medical Centre Ljubljana cardiology ward for TAVR using transfemoral approach - Voluntary agreement to participate in the study - Aged over 18 years Exclusion Criteria: - Disagreement to participate in the study - Unable to voluntarily agree to participate in the study - Unable to participate in Mini-Mental State Examination - History of alcohol abuse - Diagnosed progressive dementia - History of cerebrovascular insult

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propofol
Procedural sedation during TAVR procedure using propofol
Dexmedetomidine
Procedural sedation during TAVR procedure using dexmedetomidine

Locations

Country Name City State
Slovenia UMC Ljubljana Ljubljana

Sponsors (1)

Lead Sponsor Collaborator
University Medical Centre Ljubljana

Country where clinical trial is conducted

Slovenia, 

Outcome

Type Measure Description Time frame Safety issue
Other Length of intensive care unit stay 30 days after the TAVR procedure
Other Duration of in-hospital stay 30 days after the TAVR procedure
Primary Effect of procedural sedation with propofol or dexmedetomidine on cognitive function of patients The investigators will perform cognitive function testing (Mini-Mental State Examination Test) one day before the procedure (baseline result) and 48 hours after the procedure (assesing change from baseline result) 3 days
Primary Effect of procedural sedation with propofol or dexmedetomidine on appearance of postoperative delirium The investigators will perform CAM-ICU delirium assesment method every 12 hours for 84 hours after the procedure, assesing appearance of postoperative delirium in the first 84 hours after the procedure 84 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05465655 - Cara CDRM (Conduction Disturbance Risk Monitor) 2.0 N/A
Recruiting NCT04870424 - Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Phase 3
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Recruiting NCT05758701 - CT TAVR Abdomen Study Phase 4
Active, not recruiting NCT04281771 - Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Recruiting NCT05235555 - EffecTAVI Registry
Completed NCT05082337 - The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures N/A
Completed NCT01627691 - REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System N/A
Recruiting NCT05075590 - Coronary Access After Supra-Annular THV Implantation N/A
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Recruiting NCT05259241 - ADAPT Transcatheter Aortic Valve Intervention (TAVI & Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) N/A
Completed NCT04489914 - Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement
Recruiting NCT03649594 - Risk Stratification Post TAVI Using TEG
Completed NCT04659538 - The CAPTIS® Study - Embolic Protection in TAVR N/A
Recruiting NCT04107038 - Monitored Anesthesia Care vs. General Anesthesia for Transcatheter Aortic Valve Replacement N/A
Withdrawn NCT04268160 - GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR
Recruiting NCT02812953 - Biological Collection and Registry of Patients Who Will Have a TAVR (Transcatheter Aortic Valve Replacement) Intervention
Recruiting NCT05217888 - The Sentinel Registry